Sri Lanka Sterile Device Sterilisation Validation Requirements

1. Key takeaways

For sterile medical devices, Sri Lanka requires four additional categories of special documentation: a sterility report, a sterilisation validation protocol and report, ethylene oxide (EO) residue test data for EO-sterilised products, and a packaging integrity report. These are mandatory additions on top of the base PRD materials, and missing items directly affect the pace of assessment. None of the four can be quietly absorbed into another document: the sterility report evidences the sterile status of the product; the validation protocol and report evidence that the sterilisation process itself is effective; the EO residue data evidence that residual sterilant levels have been measured; and the packaging integrity report evidences that the sterile barrier has held. Each answers a distinct question, and reviewers check for each one separately. The four documents also share a common weakness: they expire, or their test conditions age, faster than most other dossier content, so a set that was complete at planning can be incomplete at submission. Planning the four as a set — commissioned together, reviewed together, and checked off together — is the most efficient way to keep a sterile-product submission on schedule.

• Four special documents apply to sterile devices: sterility report, sterilisation validation protocol and report, EO residue test data, and packaging integrity report — all required under GL-034, effective 2025-07-23.
• Whether a product is sterile directly affects its eligibility for the low-risk pathway under GL-037, effective 2026-05-13.
• EO residue test data is a separate data item for EO-sterilised products and is checked independently during review.
• A stability protocol and data are also required under GL-034 where applicable, and belong in the same preparation cycle as the four sterile-device documents.

2. Legal basis

The four sterile-device document requirements derive from GL-034, which took effect on 2025-07-23. The linkage between sterility and the low-risk pathway derives from GL-037, which took effect on 2026-05-13. The stability requirement returns to GL-034 and applies where applicable.

3. Expert insights

Insight one: sterility is one of the three thresholds of the low-risk pathway. The low-risk scope of GL-037 is limited to non-sterile, non-active devices without measuring functions, covering listed devices, Class I general devices, and Class A IVDs. Once a product is sterile, it cannot use the low-risk pathway even if its risk class is Class I or Class A. This surprises manufacturers who assume the risk class alone decides the pathway. It does not: sterility is an independent disqualifier. A Class I sterile device therefore faces both the full special-documentation set described in this article and the loss of the simplified pathway, a double effect that should be priced into any market-entry plan at the earliest stage.

Insight two: EO residue is an independent data item and cannot be merged into the sterilisation validation report. The rules list it separately as EO residue test data for EO-sterilised products, which indicates that reviewers verify this item on its own. A submission that buries residue results inside the validation report risks being treated as lacking the data item altogether. Preparing a distinct, clearly titled data set for EO residue — with the measurement results presented in their own document — removes the ambiguity entirely and spares the reviewer from hunting for it. In practice this item also has the longest external lead time, because it depends on testing performed after a production batch has been sterilised, which is another reason to commission it early.

Insight three: packaging integrity and sterilisation validation are two different things. Sterilisation validation proves that the sterilisation process is effective; packaging integrity proves that the barrier remained intact from sterilisation until the point of use. Both reports are required. A perfectly validated process with a failed barrier still leaves the product non-sterile at the point of clinical use, which is why the two documents answer complementary questions and neither covers for the absence of the other. When reviewing the packaging integrity report, attention belongs on the test conditions as much as on the conclusions: conditions that do not reflect the real distribution and storage environment weaken the evidence even if the report is formally valid.

Taken together, the four documents describe a single assurance story: the process makes the product sterile, the residue data show it is safe to use, and the packaging keeps it sterile until use. Drafting them as one narrative — rather than four unrelated laboratory reports — makes the dossier easier to review and reduces the likelihood of queries that arise purely from presentation.

4. Practical recommendations

• GRZAN applies the following check order for sterile-product projects: first confirm the sterilisation method and the applicable standard → then verify the completeness and validity of the sterilisation validation protocol and report → then verify the EO residue test data separately → finally verify the test conditions and validity of the packaging integrity report.
• EO residue data is the item most often missing; request it from the manufacturer well in advance.
• Track the validity of each report at the dossier level, so that an expiring report is renewed before submission rather than after a deficiency notice.
• For products intended for the low-risk pathway, confirm the sterility status first, since it decides pathway eligibility before any other document work begins.

5. Verification checklist

• □ Sterility report obtained
• □ Sterilisation validation protocol and report ready
• □ EO residue test data obtained for EO-sterilised products
• □ Packaging integrity report issued
• □ Stability and shelf-life data (where applicable) prepared

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com